OPKO closes patient recruitment in first Phase III study of Rayaldy
OPKO Health has closed patient enrolment in the first Phase III trial of Rayaldy for the treatment of patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Chronic Kidney Disease | Health | Hyperparathyroidism | Pharmaceuticals | Study | Urology & Nephrology | Vitamins